|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
|
IL101661A
(en)
|
1991-04-23 |
1998-02-08 |
Regeneron Pharma |
Method for detecting, identifying or measuring agents having neurotrophin activity
|
|
US5837821A
(en)
|
1992-11-04 |
1998-11-17 |
City Of Hope |
Antibody construct
|
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
|
DK0698097T3
(da)
|
1993-04-29 |
2001-10-08 |
Unilever Nv |
Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
|
|
IL113252A0
(en)
|
1994-04-04 |
1995-07-31 |
Regeneration Pharmaceuticals I |
Eph receptors binding ligands
|
|
CA2208783C
(en)
|
1994-12-30 |
2010-09-28 |
Planet Biotechnology, Inc. |
Methods for producing immunoglobulins containing protection proteins in plants and their use
|
|
GB9501079D0
(en)
|
1995-01-19 |
1995-03-08 |
Bioinvent Int Ab |
Activation of T-cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
EP0739981A1
(en)
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
|
|
DK0826696T3
(da)
|
1996-09-03 |
2002-09-23 |
Gsf Forschungszentrum Umwelt |
Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
|
|
JP2002505574A
(ja)
|
1997-04-30 |
2002-02-19 |
エンゾン，インコーポレイテッド |
ポリアルキレンオキシド修飾された単鎖ポリペプチド
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
DK1049787T3
(da)
|
1998-01-23 |
2005-04-04 |
Vlaams Interuniv Inst Biotech |
Antistofderivater med flere anvendelsesmuligheder
|
|
US20020142000A1
(en)
|
1999-01-15 |
2002-10-03 |
Digan Mary Ellen |
Anti-CD3 immunotoxins and therapeutic uses therefor
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
US20040116330A1
(en)
|
2001-04-27 |
2004-06-17 |
Kenichiro Naito |
Preventive/therapeutic method for cancer
|
|
AU2002319544B2
(en)
|
2001-08-10 |
2008-07-10 |
Aberdeen University |
Antigen binding domains from fish
|
|
DE60124912T2
(de)
|
2001-09-14 |
2007-06-14 |
Affimed Therapeutics Ag |
Multimerische, einzelkettige, Tandem-Fv-Antikörper
|
|
DE60127143T2
(de)
|
2001-11-14 |
2007-11-15 |
Affimed Therapeutics Ag |
Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
GB0230201D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Retargeting
|
|
US8932603B2
(en)
|
2003-02-25 |
2015-01-13 |
Vaccibody As |
Modified antibody
|
|
AU2003259718A1
(en)
|
2003-08-07 |
2005-03-07 |
Epitomics, Inc. |
Methods for humanizing rabbit monoclonal antibodies
|
|
JP2007508801A
(ja)
|
2003-10-24 |
2007-04-12 |
エスバテック・アーゲー |
受容体チロシンキナーゼ阻害剤の同定および／または確認のための方法
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
AU2005233564A1
(en)
|
2004-04-06 |
2005-10-27 |
The Regents Of The University Of California |
Orphan receptor tyrosine kinase as a target in breast cancer
|
|
WO2005118629A1
(en)
|
2004-06-02 |
2005-12-15 |
Diatech Pty Ltd |
BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
|
|
KR20130105885A
(ko)
|
2005-01-05 |
2013-09-26 |
에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. |
상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
|
|
CA2599265A1
(en)
|
2005-02-28 |
2006-09-08 |
Centocor, Inc. |
Heterodimeric protein binding compositions
|
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
RU2008110060A
(ru)
|
2005-08-15 |
2009-09-27 |
Арана Терапьютикс Лимитед (Au) |
Сконструированные антитела с каркасными участками приматов нового света
|
|
EP1940881B1
(en)
*
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
WO2008103849A2
(en)
|
2007-02-21 |
2008-08-28 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
|
WO2007051077A2
(en)
|
2005-10-28 |
2007-05-03 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
|
ES2395969T3
(es)
|
2006-03-24 |
2013-02-18 |
Merck Patent Gmbh |
Dominios de proteínas heterodiméricas genéticamente modificados
|
|
EP2007808A4
(en)
|
2006-04-14 |
2010-07-21 |
Trubion Pharmaceuticals Inc |
BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
|
|
EP2418223A3
(en)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
|
WO2007146957A2
(en)
|
2006-06-13 |
2007-12-21 |
Irm Llc |
Ror1 as a therapeutic target for lung cancer
|
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
US20100021379A1
(en)
|
2006-06-29 |
2010-01-28 |
The Regents Of The University Of California |
Chemical Antibodies for Immunotherapy and Imaging
|
|
WO2008076868A2
(en)
|
2006-12-18 |
2008-06-26 |
Abbott Laboratories |
Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
|
|
EP2139924B1
(en)
|
2007-03-29 |
2016-07-06 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
|
DK2265283T3
(da)
|
2008-03-18 |
2014-10-20 |
Seattle Genetics Inc |
Auristatin-lægemiddel-linker-konjugater
|
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
EP2316491B1
(en)
|
2008-07-18 |
2016-10-12 |
National University Corporation Nagoya University |
Cell proliferation inhibitor
|
|
RU2547600C2
(ru)
*
|
2008-10-01 |
2015-04-10 |
Эмджен Рисерч (Мьюник) Гмбх |
Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
|
|
WO2010063785A2
(en)
|
2008-12-03 |
2010-06-10 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
EP2421899B1
(en)
|
2009-04-23 |
2016-06-08 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-human ror1 antibodies
|
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
UY32808A
(es)
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
EP2496605A1
(en)
*
|
2009-11-02 |
2012-09-12 |
Oxford Biotherapeutics Ltd. |
Ror1 as therapeutic and diagnostic target
|
|
CN102712695B
(zh)
|
2009-12-18 |
2015-01-21 |
堪瑟拉公司 |
能够诱导细胞死亡的ror1生物抑制剂
|
|
SG181952A1
(en)
|
2009-12-29 |
2012-07-30 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
|
CN102330723A
(zh)
|
2010-07-13 |
2012-01-25 |
新秩序投资119股份有限公司 |
管配件
|
|
WO2012045085A1
(en)
|
2010-10-01 |
2012-04-05 |
Oxford Biotherapeutics Ltd. |
Anti-rori antibodies
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
WO2012075158A1
(en)
*
|
2010-12-01 |
2012-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric rabbit/human ror1 antibodies
|
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
US9683052B2
(en)
|
2011-03-25 |
2017-06-20 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
WO2012158818A2
(en)
*
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
US9890218B2
(en)
|
2011-06-30 |
2018-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
|
WO2013026837A1
(en)
*
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
PH12013502531A1
(en)
*
|
2011-08-23 |
2014-01-20 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
CN107586340B
(zh)
|
2011-08-23 |
2022-01-21 |
罗切格利卡特公司 |
对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
|
|
EP2787078B1
(en)
|
2011-10-31 |
2019-05-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
HRP20201004T1
(hr)
|
2011-12-20 |
2020-10-16 |
Medimmune, Llc |
Modificirani polipeptidi za skelete bispecifičnog protutijela
|
|
DK2838917T3
(da)
|
2012-04-20 |
2019-08-26 |
Merus Nv |
Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
|
|
KR20150013188A
(ko)
|
2012-05-24 |
2015-02-04 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체
|
|
US9758591B2
(en)
|
2012-08-24 |
2017-09-12 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
|
BR112015007120A2
(pt)
*
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
|
UY35148A
(es)
*
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
ES2667420T3
(es)
|
2013-02-05 |
2018-05-10 |
Engmab Sàrl |
Anticuerpos biespecíficos contra cd3epsilon y bcma
|
|
UA119320C2
(uk)
|
2013-02-26 |
2019-06-10 |
Рош Глікарт Аг |
Активуюча т-клітини біспецифічна антигензв'язувальна молекула
|
|
US10351626B2
(en)
|
2013-03-14 |
2019-07-16 |
The Scripps Research Institute |
Targeting agent antibody conjugates and uses thereof
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
UA117289C2
(uk)
*
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
DK3107938T3
(da)
*
|
2014-05-28 |
2022-07-11 |
Zymeworks Inc |
Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
|
|
SMT202400235T1
(it)
*
|
2014-08-04 |
2024-07-09 |
Hoffmann La Roche |
Molecole bispecifiche leganti l’antigene di attivazione delle cellule t
|
|
EP2982692A1
(en)
*
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
CA2960756C
(en)
*
|
2014-09-15 |
2023-08-01 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
AU2015329965A1
(en)
|
2014-10-09 |
2017-04-27 |
Engmab Sàrl |
Bispecific antibodies against CD3epsilon and ROR1
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
EP3670535A1
(en)
|
2015-08-03 |
2020-06-24 |
EngMab Sàrl |
Monoclonal antibodies against bcma
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
WO2020219978A1
(en)
|
2019-04-25 |
2020-10-29 |
Celgene Corporation |
Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies
|
|
CA3160137A1
(en)
|
2019-11-05 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of treatment with antibodies against bcma and cd3
|
|
WO2021092060A1
(en)
|
2019-11-05 |
2021-05-14 |
Engmab Sarl |
Methods of treatment
|
|
MX2022009784A
(es)
|
2020-02-12 |
2022-09-09 |
Bristol Myers Squibb Co |
Terapia anti-bcma en trastornos autoinmunes.
|
|
US20230172923A1
(en)
|
2020-04-30 |
2023-06-08 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|